Home    Back

Aciclovir    (DrugBank: Aciclovir)

2 diseases
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1
60Aplastic anemia1

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3,050 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02205489
(ClinicalTrials.gov)		October 201429/7/2014Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADASingle Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Associated Reactions (IARs) In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With LEMTRADARelapsing-remitting Multiple SclerosisDrug: Alemtuzumab GZ402673;Drug: cetirizine;Drug: ranitidine;Drug: methylprednisolone;Drug: aciclovir;Drug: esomeprazole;Drug: ibuprofen;Drug: paracetamolGenzyme, a Sanofi CompanyNULLCompleted18 YearsN/ABoth58Phase 4Belgium;France;Netherlands;Spain

60. Aplastic anemia    [ 218 clinical trials,   362 drugs,   (DrugBank: 81 drugs),   39 drug target genes,   155 drug target pathways]
Searched query = "Aplastic anemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 218 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2011-005152-34-ES
(EUCTR)		26/03/201222/11/2011Clinical trial to reduce duration of antibiotic therapy in in-hospital patients with haematological diseases that develop fever and low white blood cell count (neutropenia).Randomized open label clinical trial directed to optimize the duration of empirical antimicrobial therapy in haematologic patients with febrile neutropenia In-hospital adult patients diagnosed with acute leukemia, lymphoproliferative syndrome, multiple myeloma, myelodysplastic syndrome, aplastic anemia or who have received autologous or allogeneic transplantation of hematopoietic progenitors, with febrile neutropenia without etiological diagnosis.
MedDRA version: 14.0;Level: PT;Classification code 10016288;Term: Febrile neutropenia;System Organ Class: 10005329 - Blood and lymphatic system disorders
MedDRA version: 14.0;Level: LLT;Classification code 10066156;Term: Empiric treatment;System Organ Class: 10042613 - Surgical and medical procedures;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]		INN or Proposed INN: ACICLOVIR
Other descriptive name: ACICLOVIR
INN or Proposed INN: AMIKACIN
Other descriptive name: AMIKACIN
INN or Proposed INN: AMPHOTERICINE B, LIPOSOME
Other descriptive name: AMPHOTERICINE B, LIPOSOME
INN or Proposed INN: CASPOFUNGIN ACETATE
Other descriptive name: CASPOFUNGIN ACETATE
INN or Proposed INN: CEFEPIME DIHYDROCHLORIDE MONOHYDRATE
Other descriptive name: CEFEPIME DIHYDROCHLORIDE MONOHYDRATE
INN or Proposed INN: CIPROFLOXACIN
Other descriptive name: CIPROFLOXACIN
INN or Proposed INN: TRIMETHOPRIM SULFATE
Other descriptive name: TRIMETHOPRIM SULFATE
INN or Proposed INN: SULFAMETH		José Miguel Cisneros HerrerosNULLNot RecruitingFemale: yes
Male: yes		Phase 3Spain